[8-K] Jack in the Box Inc. Reports Material Event

Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) filed a Form 8-K on August 6, 2025. Under Item 2.02, the company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is expressly not deemed “filed” for liability purposes under Section 18 of the Exchange Act. Item 9.01 lists the exhibits included in the filing, namely the press release and the cover-page Inline XBRL data file. No actual financial figures, guidance, or narrative commentary are contained within the 8-K itself.

The filing is procedural, serving mainly to make the earnings release publicly available while limiting legal exposure. Investors must review Exhibit 99.1 for quantitative details.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishes Q2-25 earnings release; no numbers disclosed here.

The 8-K is purely administrative, triggering no immediate valuation insight because it omits the underlying financial metrics. Management uses Item 2.02 to ensure Reg FD compliance while keeping the furnished material outside Section 18 liability. Impact on the stock will depend entirely on the content of Exhibit 99.1, which is not provided. Therefore, the filing itself is neutral and non-impactful from an analytical standpoint.

FALSE000080788200008078822025-08-062025-08-06

_____________________________________________________________________________________

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2025

JACK IN THE BOX INC.

(Exact name of registrant as specified in its charter)

_________________

Delaware			1-9390			95-2698708
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

9357 Spectrum Center Blvd, San Diego, CA 92123

(Address of principal executive offices) (Zip Code)

(858) 571-2121

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			JACK			NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

______________________________________________________________________

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 6, 2025, Jack in the Box Inc. issued a press release announcing its third quarter fiscal 2025 financial results and disclosing other information.

A copy of the press release is attached as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

Exhibit No.			Description
99.1			Press Release of Jack in the Box Inc. dated August 6, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

JACK IN THE BOX INC.

/s/    Lance Tucker

Lance Tucker

Chief Executive Officer (principal executive officer)

Date: August 6, 2025

FAQ

Why did Artiva Biotherapeutics (ARTV) file a Form 8-K on August 6, 2025?

To furnish its press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02.

Does the 8-K include Artiva’s Q2 2025 financial numbers?

No. The filing references the press release as Exhibit 99.1, but no figures appear in the body of the 8-K.

Is the furnished press release considered "filed" with the SEC?

No. Artiva states the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.

What exhibits accompany the 8-K?

Exhibit 99.1 (press release dated August 6, 2025) and Exhibit 104 (cover-page Inline XBRL data file).

How should investors obtain the actual earnings details?

Investors need to read Exhibit 99.1, which contains the full Q2 2025 financial results.